Elan Corporation PLC  A joint venture to develop and commercialize a specific therapeutic protein. Athersys is contributing the protein production capabilities of its RAGE technology and Elan is contributing a proprietary drug delivery technology.

Medarex, Inc.  A collaboration to develop novel therapeutics produced through the joint application of Medarex's HuMAb Mouse® technology and Athersys' RAGE technology. The companies plan to jointly discover, develop and commercialize fully human antibodies as therapeutics.

Acorda Therapeutics  A functional genomics collaboration focused on the discovery of validated drug targets to treat certain central nervous system disorders, including spinal cord injuries and multiple sclerosis. Athersys and Acorda will jointly own therapeutic products or validated targets identified and developed through the collaboration.

University of Alabama at Birmingham  A collaboration to jointly conduct high-throughput structural analysis of validated drug targets.

University of Rochester  A research collaboration with Dr. Mark Noble of the University of Rochester under a Phase I SBIR Grant to Athersys to discover and validate novel CNS drug targets.

Molecumetics  Athersys will provide Molecumetics with cell lines expressing up to 12 validated drug targets produced using the RAGE-Validated Targets technology. Molecumetics plans to use its chemistry based "screen-to-IND" technology platform to develop novel small molecule drug candidates against the validated targets. Targets may be licensed by Molecumetics or co-developed with Athersys.

Cleveland Clinic  A collaboration to discover and functionally validate novel drug targets that play an important role in cancer and inflammation. Athersys scientists will work with researchers under the direction of Dr. George R. Stark, Chairman of the Lerner Research Institute at CCF, to rapidly and efficiently identify novel drug targets that regulate certain cell-signaling and disease pathways. Athersys has an exclusive option to commercialize novel therapeutics that result from the collaboration.

Bristol-Myers Squibb Company  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Center for Stem Cell and Regenerative Medicine  is a Founding member of CSCRM and is actively developing therapeutics based on the Multipotent Adult Progenitor Cell (MAPC) technology, originally developed by Dr. Catherine Verfaillie and colleagues at the University of Minnesota and licensed exclusively to Athersys. The company has numerous collaborations with CSCRM investigators and institutions to rapidly advance its product candidates to the clinic.